CH694589A5 - Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. - Google Patents
Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. Download PDFInfo
- Publication number
- CH694589A5 CH694589A5 CH02367/01A CH23672000A CH694589A5 CH 694589 A5 CH694589 A5 CH 694589A5 CH 02367/01 A CH02367/01 A CH 02367/01A CH 23672000 A CH23672000 A CH 23672000A CH 694589 A5 CH694589 A5 CH 694589A5
- Authority
- CH
- Switzerland
- Prior art keywords
- antibody
- cancer
- erbb2
- cells
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14131699P | 1999-06-25 | 1999-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH694589A5 true CH694589A5 (de) | 2005-04-15 |
Family
ID=22495168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH02367/01A CH694589A5 (de) | 1999-06-25 | 2000-06-23 | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
Country Status (33)
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003034977A2 (en) * | 2001-10-26 | 2003-05-01 | Altarex Medical Corp. | Combination therapy for treating disease |
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
CH694589A5 (de) * | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
EP1191944A2 (en) * | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
US6825333B1 (en) | 1999-08-20 | 2004-11-30 | Chiron Corporation | EGFH2 genes and gene products |
NZ517150A (en) * | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
DK1282443T3 (da) | 2000-05-19 | 2010-01-04 | Genentech Inc | Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi |
EP1228766A1 (en) * | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2003087338A2 (en) * | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
ITTO20020340A1 (it) * | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
NO340576B1 (no) * | 2002-07-11 | 2017-05-15 | Hoffmann La Roche | Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament |
DK2263691T3 (da) * | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
RU2326691C2 (ru) * | 2002-07-18 | 2008-06-20 | Хеликс Биофарма Корп. | Использование уреазы для ингибирования роста раковых клеток |
US7264800B2 (en) | 2002-07-18 | 2007-09-04 | Helix Biopharma Corporation | Method and composition for inhibiting cancer cell growth |
KR101115797B1 (ko) | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법 |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP4790413B2 (ja) * | 2002-10-08 | 2011-10-12 | イミューノメディクス、インコーポレイテッド | 抗体療法 |
EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
JP2007517767A (ja) * | 2003-03-11 | 2007-07-05 | ダナ ファーバー キャンサー インスティテュート | ウイルスの病原性の阻害方法 |
EP2404615A1 (en) * | 2003-04-23 | 2012-01-11 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
AT500651B9 (de) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
SI3095793T1 (sl) | 2003-07-28 | 2020-07-31 | Genentech, Inc. | Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A |
EP1658075A4 (en) * | 2003-08-29 | 2008-03-05 | Cedars Sinai Medical Center | COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER AND OTHER PHYSIOLOGICAL STATES BASED ON THE MODULATION OF THE PPAR GAMMA PATH AND THE HERINE KINASE AXIS |
US7790855B2 (en) * | 2003-09-18 | 2010-09-07 | Macrogenics, Inc. | KID3 and KID3 antibodies that bind thereto |
KR20070003806A (ko) * | 2003-11-28 | 2007-01-05 | 미트라 메디컬 아베 | Erb 항원의 표적화 |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
EP1922410A2 (en) | 2005-08-15 | 2008-05-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
KR101164820B1 (ko) | 2005-09-22 | 2012-07-12 | 삼성전자주식회사 | 디스플레이장치 |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2007081608A2 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
AU2007297565A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
AU2007259171A1 (en) * | 2006-06-05 | 2007-12-21 | F. Hoffmann-La Roche, Ag | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
CA2665528C (en) | 2006-10-12 | 2018-01-23 | The University Of Tokyo | Diagnosis and treatment of cancer using anti-ereg antibody |
HUE034263T2 (en) | 2006-10-27 | 2018-02-28 | Genentech Inc | Antibodies and immunoconjugates and their applications |
SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CA2690449A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
KR20150008503A (ko) | 2007-10-30 | 2015-01-22 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
CN108864285A (zh) | 2008-01-03 | 2018-11-23 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
WO2009099728A1 (en) | 2008-01-31 | 2009-08-13 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
EP2260111B2 (en) * | 2008-03-14 | 2022-03-23 | Genentech, Inc. | Genetic variations associated with drug resistance |
CA3146422A1 (en) * | 2008-03-18 | 2009-09-24 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
KR20120127543A (ko) | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CA2734275A1 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
EP2417164A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-2/anti-c-met antibodies |
CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
KR20180010324A (ko) | 2009-08-11 | 2018-01-30 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
AR077848A1 (es) * | 2009-08-15 | 2011-09-28 | Genentech Inc | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado |
EP2473617B1 (en) | 2009-09-01 | 2020-02-26 | F.Hoffmann-La Roche Ag | Enhanced protein purification through a modified protein a elution |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
CA2776385C (en) | 2009-10-07 | 2019-04-09 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
ES2639056T3 (es) * | 2009-10-28 | 2017-10-25 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-EGFR y sus usos |
BR112012010153B1 (pt) | 2009-11-05 | 2022-05-03 | Genentech, Inc | Método de produção de um anticorpo |
RS56741B1 (sr) | 2009-11-13 | 2018-03-30 | Daiichi Sankyo Europe Gmbh | Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3 |
KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
EP2532365B1 (en) * | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
EP2536748B1 (en) * | 2010-02-18 | 2014-08-20 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
BR112012021873B8 (pt) | 2010-03-22 | 2021-09-14 | Genentech Inc | composição de matéria, artigo de manufatura, métodos para preparar uma composição, para aumentar a estabilidade de uma proteína em solução aquosa livre de polissorbato e para prevenir ou reduzir a agregação de uma proteína em solução aquosa livre de polissorbato |
BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
JP6050226B2 (ja) | 2010-05-28 | 2016-12-21 | ジェネンテック, インコーポレイテッド | Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加 |
JP6048973B2 (ja) | 2010-06-03 | 2016-12-27 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法 |
CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
KR101924653B1 (ko) | 2010-06-24 | 2018-12-03 | 제넨테크, 인크. | 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법 |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
BR112013012422A2 (pt) | 2010-12-21 | 2016-08-30 | Hoffmann La Roche | "método para produzir uma preparação de anticorpo e anticorpo anti-her2" |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JP6162044B2 (ja) | 2010-12-23 | 2017-07-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 結合剤 |
CN103476777B (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 |
CN103649326B (zh) * | 2011-03-08 | 2016-08-17 | 宾夕法尼亚大学理事会 | 用于治疗和诊断用途的抗体样蛋白 |
CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
AU2012322797B2 (en) | 2011-10-14 | 2016-04-21 | Genentech, Inc. | Uses for and article of manufacture including HER2 dimerization inhibitor Pertuzumab |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
CN104093743B (zh) | 2011-11-23 | 2018-04-24 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
RU2014126098A (ru) | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
CN104125963B (zh) | 2011-12-22 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 使用离子交换膜层析改进下游蛋白质纯化步骤的方法 |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
CA2863287A1 (en) | 2012-01-31 | 2013-08-08 | Smithkline Beecham (Cork) Limited | Method of treating cancer |
EP2638916A1 (en) | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
KR101505157B1 (ko) | 2012-05-08 | 2015-03-24 | 주식회사 종근당 | 항―ErbB2 항체 변이체 |
RU2630975C2 (ru) | 2012-05-16 | 2017-09-15 | Новартис Аг | Режим дозирования pi-3 киназы |
CN104813168B (zh) | 2012-11-30 | 2017-10-20 | 霍夫曼-拉罗奇有限公司 | 需要pd‑l1抑制剂综合疗法的患者的鉴定 |
JP6231129B2 (ja) | 2013-01-10 | 2017-11-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 脂肪酸シンターゼ阻害剤 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
CN104628846B (zh) | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
PL3480215T3 (pl) | 2013-11-19 | 2021-12-13 | Remegen Co., Ltd. | Przeciwciało anty-HER2 i jego koniugat |
US10947319B2 (en) | 2013-11-27 | 2021-03-16 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting HER2 |
KR20160095035A (ko) | 2013-12-06 | 2016-08-10 | 노파르티스 아게 | 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법 |
CA2928794C (en) | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
WO2015128837A1 (en) | 2014-02-26 | 2015-09-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
CA2941687A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
BR112016022910A2 (pt) | 2014-04-11 | 2017-10-17 | Medimmune Llc | anticorpos contra her2 biespecíficos |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
KR101515535B1 (ko) | 2015-01-28 | 2015-05-06 | 주식회사 종근당 | 항―ErbB2 항체 변이체 |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
US11028182B2 (en) | 2015-05-13 | 2021-06-08 | Zymeworks Inc. | Antigen-binding constructs targeting HER2 |
US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
AU2016336959A1 (en) * | 2015-10-13 | 2018-04-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
MX2018005298A (es) | 2015-11-02 | 2018-06-22 | Novartis Ag | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 組合せ処置およびその方法 |
TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
CN105646704B (zh) * | 2015-12-28 | 2019-11-15 | 广西医科大学 | 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法 |
AU2017219749B2 (en) | 2016-02-19 | 2022-01-06 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US20190091227A1 (en) * | 2016-03-15 | 2019-03-28 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
WO2017181116A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
CN109476744B (zh) * | 2016-05-12 | 2023-04-11 | 新加坡科技研究局 | 抗erbb-2抗体及其用途 |
JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
WO2018066626A1 (ja) | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
JP7069476B2 (ja) | 2017-01-06 | 2022-05-18 | 博奥信生物技▲術▼(南京)有限公司 | ErbB2抗体およびその使用 |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
CR20190481A (es) | 2017-03-22 | 2020-01-06 | Genentech Inc | Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares |
JP2020516648A (ja) | 2017-04-13 | 2020-06-11 | シワ コーポレーション | ヒト化モノクローナル終末糖化産物抗体 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
JP7204651B2 (ja) | 2017-08-23 | 2023-01-16 | 第一三共株式会社 | 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法 |
US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
AU2018327171B2 (en) | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
CN107789631B (zh) * | 2017-11-03 | 2021-03-16 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双表位抗体-药物偶联物及其应用 |
CA3085432A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd16-binding molecules and their use in the treatment of disease |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
EP3752196A4 (en) | 2018-02-15 | 2022-03-23 | MacroGenics, Inc. | VARIANT DOMAINS OF CD3 BINDING AND THEIR USE IN MULTITHERAPIES FOR THE TREATMENT OF A DISEASE |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
BR112020024061A2 (pt) | 2018-05-28 | 2021-02-17 | Daiichi Sankyo Company, Limited | agente terapêutico para câncer com her2 mutado |
KR20210035854A (ko) | 2018-07-23 | 2021-04-01 | 트레비 테라퓨틱스, 인코포레이티드 | 만성 기침, 무호흡증 및 호흡곤란의 치료 |
TW202019972A (zh) | 2018-07-25 | 2020-06-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之有效的製造方法 |
EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
KR20210038625A (ko) | 2018-07-31 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 |
CN112512587A (zh) | 2018-08-06 | 2021-03-16 | 第一三共株式会社 | 抗体药物缀合物和微管蛋白抑制剂的组合 |
WO2020040245A1 (ja) | 2018-08-23 | 2020-02-27 | 第一三共株式会社 | 抗体薬物複合体の感受性マーカー |
EP3856760A1 (en) | 2018-09-25 | 2021-08-04 | AbSci, LLC | Protein purification methods |
WO2020084503A1 (en) | 2018-10-26 | 2020-04-30 | Cadila Healthcare Limited | A composition comprising antibody with reduced level of basic variants thereof |
TW202034959A (zh) | 2018-12-11 | 2020-10-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與parp抑制劑之組合 |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
JP2022524921A (ja) | 2019-02-01 | 2022-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン |
MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
CN112007169B (zh) * | 2019-05-30 | 2022-03-08 | 湖南大学 | 一种核酸适配体药物偶联物及其制备方法和用途 |
CN110205302B (zh) * | 2019-06-24 | 2021-03-23 | 扬州大学 | 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用 |
WO2020261097A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
CN110551214A (zh) * | 2019-08-27 | 2019-12-10 | 杨澜 | 一种人源化抗Periostin单克隆抗体、及其制备方法和应用 |
EP4096718A1 (en) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
KR20230043109A (ko) | 2020-06-24 | 2023-03-30 | 아스트라제네카 유케이 리미티드 | 항체-약물 접합체 및 atr 억제제의 조합 |
US20230293714A1 (en) | 2020-07-20 | 2023-09-21 | Daiichi Sankyo Company, Limited | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
KR20230084163A (ko) | 2020-10-09 | 2023-06-12 | 아스트라제네카 유케이 리미티드 | 항체-약물 접합체와 parp1 선택적 억제제의 조합 |
JPWO2022102634A1 (US20050276830A1-20051215-C00018.png) | 2020-11-11 | 2022-05-19 | ||
TW202334238A (zh) | 2021-11-30 | 2023-09-01 | 日商第一三共股份有限公司 | 蛋白酶分解性遮蔽抗體 |
WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2023218378A1 (en) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
IL74201A0 (en) | 1984-01-30 | 1985-04-30 | Icrf Patents Limited | Polypeptides for the detection and control of mammalian cell growth |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のneu関連タンパク質の検出及び定量 |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
CA2120745A1 (en) | 1992-06-30 | 1994-01-06 | Philip G. Kasprzyk | A combination of anti-erbb-2 monoclonal antibodies and method of using |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
CN1151842C (zh) | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
DE69732711T2 (de) * | 1996-07-12 | 2006-03-16 | Genentech, Inc., South San Francisco | Gamma-heregulin |
NZ334148A (en) * | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
CA2269204C (en) * | 1996-10-18 | 2012-01-24 | Genentech, Inc. | Anti-erbb2 antibodies |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1999019488A1 (en) | 1997-10-15 | 1999-04-22 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
EP1191944A2 (en) * | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
CH694589A5 (de) * | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
CA2383493C (en) * | 1999-06-25 | 2010-08-10 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
NZ517150A (en) * | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
-
2000
- 2000-06-23 CH CH02367/01A patent/CH694589A5/de not_active IP Right Cessation
- 2000-06-23 NZ NZ531426A patent/NZ531426A/en not_active IP Right Cessation
- 2000-06-23 AU AU57632/00A patent/AU784045B2/en active Active
- 2000-06-23 SI SI200031040T patent/SI1189641T1/sl unknown
- 2000-06-23 AT AT00943115T patent/ATE437655T1/de active
- 2000-06-23 RU RU2002100905/15A patent/RU2270029C2/ru active Protection Beyond IP Right Term
- 2000-06-23 BR BRPI0012198A patent/BRPI0012198B8/pt not_active IP Right Cessation
- 2000-06-23 WO PCT/US2000/017366 patent/WO2001000245A2/en active IP Right Grant
- 2000-06-23 KR KR1020077020771A patent/KR100797308B1/ko active IP Right Review Request
- 2000-06-23 CN CN200910126199.1A patent/CN101518653B/zh not_active Expired - Lifetime
- 2000-06-23 KR KR1020017016490A patent/KR100850389B1/ko active Protection Beyond IP Right Term
- 2000-06-23 EP EP09007811A patent/EP2112167A3/en not_active Withdrawn
- 2000-06-23 CN CN2007101411129A patent/CN101121021B/zh not_active Expired - Lifetime
- 2000-06-23 PL PL384502A patent/PL203326B1/pl unknown
- 2000-06-23 GE GEAP200011523A patent/GEP20104998B/en unknown
- 2000-06-23 DK DK00943115.6T patent/DK1189641T5/da active
- 2000-06-23 GB GB0200506A patent/GB2368796B/en not_active Expired - Lifetime
- 2000-06-23 ES ES00943115T patent/ES2329437T3/es not_active Expired - Lifetime
- 2000-06-23 SI SI200031088T patent/SI2283866T1/sl unknown
- 2000-06-23 CA CA002376596A patent/CA2376596C/en not_active Expired - Lifetime
- 2000-06-23 MX MXPA01013458A patent/MXPA01013458A/es active IP Right Grant
- 2000-06-23 DE DE10084743T patent/DE10084743T1/de not_active Withdrawn
- 2000-06-23 JP JP2001505952A patent/JP4283474B2/ja not_active Expired - Lifetime
- 2000-06-23 CZ CZ20014596A patent/CZ299702B6/cs unknown
- 2000-06-23 CN CNA2007101411114A patent/CN101121750A/zh active Pending
- 2000-06-23 CA CA2727172A patent/CA2727172A1/en not_active Abandoned
- 2000-06-23 HU HU0201695A patent/HU226742B1/hu active Protection Beyond IP Right Term
- 2000-06-23 DE DE60042648T patent/DE60042648D1/de not_active Expired - Lifetime
- 2000-06-23 PL PL352321A patent/PL204629B1/pl unknown
- 2000-06-23 SI SI200031080T patent/SI2283867T1/sl unknown
- 2000-06-23 AR ARP000103157A patent/AR024464A1/es active IP Right Grant
- 2000-06-23 IL IL14695400A patent/IL146954A0/xx unknown
- 2000-06-23 EP EP00943115A patent/EP1189641B1/en not_active Expired - Lifetime
- 2000-06-23 TR TR2001/03756T patent/TR200103756T2/xx unknown
- 2000-06-23 CN CNB008118981A patent/CN100340575C/zh not_active Expired - Lifetime
- 2000-06-23 NZ NZ516830A patent/NZ516830A/en not_active IP Right Cessation
- 2000-06-23 BR BR122014028365A patent/BR122014028365B8/pt active IP Right Grant
- 2000-06-23 PT PT00943115T patent/PT1189641E/pt unknown
- 2000-06-23 AT AT0911000A patent/AT500848B1/de not_active IP Right Cessation
-
2001
- 2001-11-28 ZA ZA200109786A patent/ZA200109786B/en unknown
- 2001-12-06 IL IL146954A patent/IL146954A/en active Protection Beyond IP Right Term
- 2001-12-13 ZA ZA200110263A patent/ZA200110263B/xx unknown
- 2001-12-21 NO NO20016329A patent/NO328377B1/no not_active IP Right Cessation
-
2002
- 2002-08-08 HK HK02105805.2A patent/HK1044888A1/xx not_active IP Right Cessation
-
2005
- 2005-10-25 RU RU2005132788/15A patent/RU2430739C9/ru active
- 2005-12-07 AU AU2005242195A patent/AU2005242195B2/en not_active Expired
-
2008
- 2008-12-26 JP JP2008333670A patent/JP2009142280A/ja not_active Withdrawn
-
2009
- 2009-03-03 IL IL197359A patent/IL197359A0/en unknown
- 2009-05-05 NO NO20091792A patent/NO336040B1/no not_active IP Right Cessation
- 2009-10-20 CY CY20091101084T patent/CY1109525T1/el unknown
-
2013
- 2013-03-07 LU LU92164C patent/LU92164I2/fr unknown
- 2013-03-08 FR FR13C0016C patent/FR13C0016I2/fr active Active
- 2013-03-08 BE BE2013C020C patent/BE2013C020I2/fr unknown
- 2013-03-11 CY CY2013010C patent/CY2013010I1/el unknown
- 2013-03-12 NO NO2013005C patent/NO2013005I1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT500848B1 (de) | Humanisierte anti-erbb2-antikörper | |
DE60033658T2 (de) | Behandlung von prostata-krebs mit anti-erbb2 antikörpern | |
US7537931B2 (en) | Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies | |
US20070184055A1 (en) | Treatment with anti-erbb2 antibodies | |
US20040013667A1 (en) | Treatment with anti-ErbB2 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |